Verified Researcher Certificate
Active ResearchRank profile with at least one indexed scholarly output
RESEARCHER PUBLIC RESEARCH PROFILE● Verified public profile
RRK-A-5022-3761-49
Kausik Umanath
Works56
Citations2,739
h-index19
i10-index26
2-year citedness1.57
Mean FWCI*13.15
Top 1%*8
Top 10%*19
ResearchRank IDRRK-A-5022-3761-49
Observed nameKausik Umanath
ORCID0000-0003-3940-1680
Current / last-known institutionIndiana University Indianapolis, Indiana University School of Medicine
Research topicsChronic Kidney Disease and Diabetes · Blood Pressure and Hypertension Studies · Parathyroid Disorders and Treatments · Acute Kidney Injury Research · Dialysis and Renal Disease Management
Name variantsK Umanath, K. Umanath, Kausik Umanath
FULL PROFILE ANALYSIS
Kausik Umanath - detailed research intelligence
Identity, scholarly output, impact indicators, affiliations, topics and publication evidence for this ResearchRank record.
Profile typeResearcher
Works56
Citations2,739
h-index19
i10-index26
Current / last-known affiliationIndiana University Indianapolis, Indiana University School of Medicine
ORCID0000-0003-3940-1680
Name variantsK Umanath, K. Umanath, Kausik Umanath
Primary research topics
Chronic Kidney Disease and DiabetesBlood Pressure and Hypertension StudiesParathyroid Disorders and TreatmentsAcute Kidney Injury ResearchDialysis and Renal Disease Management
Chronic Kidney Disease and DiabetesBlood Pressure and Hypertension StudiesParathyroid Disorders and TreatmentsAcute Kidney Injury ResearchDialysis and Renal Disease Management
RESEARCH ACHIEVEMENT SNAPSHOT
Evidence-backed profile highlights
This public profile presents scholarly evidence and recognition indicators without displaying certificate prices or checkout controls.
Research Output Certificate
At least 10 indexed scholarly works
Citation Impact Certificate
At least 100 indexed citations
h-index Achievement Certificate
h-index of 10 or higher
Sustained Research Output Certificate
At least 50 indexed scholarly outputs
Public profile: Research metrics and recognition evidence are shown for professional sharing. Commercial pricing and registration controls are intentionally omitted.
Extended publication analytics and related-profile intelligence are loading in the background. The full profile details below remain available even if the live analytics service is temporarily slow.
TOP-CITED OUTPUT
Full profile view · up to 25 leading worksResearch works
Update on Diabetic Nephropathy: Core Curriculum 2018Article · 2018 · 981 citations · Open access · FWCI 62.8538 · Full text ↗
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathyArticle · 2021 · 420 citations · Open access · FWCI 45.6576 · Full text ↗
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsArticle · 2020 · 194 citations · Open access · FWCI 19.3018 · Full text ↗
Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT)Article · 2017 · 131 citations · Open access · FWCI 16.1486 · Full text ↗
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trialArticle · 2021 · 121 citations · Open access · FWCI 17.1002 · Full text ↗
Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRDArticle · 2015 · 118 citations · Open access · FWCI 13.3417 · Full text ↗
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney functionArticle · 2021 · 92 citations · Open access · FWCI 12.8252 · Full text ↗
Orthostatic changes in systolic blood pressure among SPRINT participants at baselineArticle · 2016 · 81 citations · Open access · FWCI 5.4993 · Full text ↗
Association of Intensive vs Standard Blood Pressure Control With Magnetic Resonance Imaging Biomarkers of Alzheimer DiseaseArticle · 2021 · 74 citations · Open access · FWCI 9.4979 · Full text ↗
Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adultsArticle · 2016 · 67 citations · Open access · FWCI 6.6893 · Full text ↗
The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical TrialArticle · 2015 · 51 citations · Open access · FWCI 6.6274 · Full text ↗
Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non–Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial)Article · 2015 · 50 citations · Open access · FWCI 4.0341 · Full text ↗
High SARS-CoV-2 Viral Load in Urine Sediment Correlates with Acute Kidney Injury and Poor COVID-19 OutcomeArticle · 2021 · 42 citations · Open access · FWCI 2.8478 · Full text ↗
Pyridoxamine Dihydrochloride in Diabetic Nephropathy (PIONEER-CSG-17): Lessons Learned from a Pilot StudyArticle · 2014 · 32 citations · FWCI 3.426 · Full text ↗
Pharmacological Effects of Ex Vivo Mesenchymal Stem Cell Immunotherapy in Patients with Acute Kidney Injury and Underlying Systemic InflammationArticle · 2021 · 30 citations · Open access · FWCI 2.8039 · Full text ↗
Self-Motivation Is Associated With Phosphorus Control in End-Stage Renal DiseaseArticle · 2015 · 29 citations · Open access · FWCI 3.4578 · Full text ↗
“Dip” in eGFR: Stay the Course With SGLT-2 InhibitionEditorial · 2022 · 26 citations · Full text ↗
Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costsArticle · 2014 · 24 citations · Open access · FWCI 3.9531 · Full text ↗
Rationale and study design of a three‐period, 58‐week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysisArticle · 2012 · 24 citations · FWCI 5.0512 · Full text ↗
Rituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathyArticle · 2014 · 19 citations · Open access · FWCI 1.8445 · Full text ↗
Health care providers’ support of patients’ autonomy, phosphate medication adherence, race and gender in end stage renal diseaseArticle · 2016 · 18 citations · Open access · FWCI 2.4378 · Full text ↗
Multinephron Segment Diuretic Therapy to Overcome Diuretic Resistance in Acute Heart Failure: A Single-Center ExperienceArticle · 2021 · 17 citations · FWCI 2.0113 · Full text ↗
Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial DataArticle · 2015 · 16 citations · Open access · FWCI 1.4407 · Full text ↗
Finerenone in Patients With Chronic Kidney Disease Due to Glomerular DiseasesArticle · 2026 · 11 citations · Open access · FWCI 53.6178 · Full text ↗
Diabetic Kidney Disease: The Tiger May Have New StripesEditorial · 2018 · 11 citations · Full text ↗